Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923131 | PMC |
| http://dx.doi.org/10.1128/AAC.00103-18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010-2021.
Front Antibiot
August 2024
The Medical School, University of Jordan, Amman, Jordan.
Objectives: To evaluate the antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.
Methods: Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards.
A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa.
J Antimicrob Chemother
January 2025
Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Objectives: To develop a scoring system to predict resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa strains isolated from respiratory specimens.
Methods: A case-control study was conducted to evaluate the risk factors associated with resistance to ceftolozane/tazobactam. Patients with P.
Antimicrobial activity of imipenem/relebactam and comparator agents against Gram-negative isolates collected from pediatric patients: SMART 2018-2022 Global Surveillance.
J Pediatric Infect Dis Soc
January 2025
IHMA, Schaumburg, IL, USA.
Objectives: To evaluate the in vitro susceptibility of recent Gram-negative pathogens collected from pediatric patients to imipenem/relebactam (IMI/REL) and comparator agents.
Methods: From 2018 to 2022, 254 hospitals in 62 countries collected Enterobacterales or P. aeruginosa isolates from patients <18 years old as part of the SMART global surveillance program.
Antibiotic Resistance Trends in Carbapenem-Resistant Gram-Negative Pathogens and Eight-Year Surveillance of XDR Bloodstream Infections in a Western Greece Tertiary Hospital.
Pathogens
December 2024
Department of Internal Medicine, University Hospital of Patras, 265 04 Patras, Greece.
: The increased prevalence of antibiotic resistance among Gram-negative bacteria presents a severe public health challenge, leading to increased mortality rates, prolonged hospital stays, and higher medical costs. In Greece, the issue of multidrug-resistant Gram-negative bacteria is particularly alarming, exacerbated by overuse of antibiotics and inadequate infection control measures. This study aimed to detect the prevalence of extensively drug-resistant (XDR) Gram-negative bacteria in a tertiary hospital in Western Greece over the last eight years from 2016 to 2023.
View Article and Find Full Text PDFDetection of carbapenemases in Enterobacterales susceptible in vitro to meropenem.
Enferm Infecc Microbiol Clin (Engl Ed)
January 2025
Unidade de Microbiologia do Serviço de Patologia Clínica do Hospital de Clínicas de Porto Alegre (HCPA), Ramiro Barcelos, Porto Alegre, Brazil.
Introduction: Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.
Methods: We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!